Thieblemont, V.C., Dumontet, C., Saad, H., Roch, N., Bouafia, F., Arnaud, P., … Coiffier, B. (2002). Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 30, 769–775.doi: 10.1038/sj.bmt.1703757
Patients in the study group received 740 mg/m2 IV amifostine prior to 200 mg/m2 melphalan.
This study was conducted betwen September 1999 and December 2001.
This was a prospective, comparative, non-randomized controlled, phase 2 trial conducted at a single institution.